Kitabis pak and Infection - a phase IV clinical study of FDA data

Summary:

Infection is reported as a side effect among people who take Kitabis pak (tobramycin), especially for people who are male, 10-19 old, have been taking the drug for < 1 month also take Pulmozyme, and have Cystic fibrosis.

The phase IV clinical study analyzes which people have Infection when taking Kitabis pak. It is created by eHealthMe based on reports of 921 people who have side effects when taking Kitabis pak from the FDA, and is updated regularly.

What is Kitabis pak?

Kitabis pak has active ingredients of tobramycin. eHealthMe is studying from 921 Kitabis pak users. Check the latest studies of Kitabis pak.

What is Infection?

Infection is found to be associated with 2,499 drugs and 2,595 conditions by eHealthMe. Check the latest studies of Infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

921 people reported to have side effects when taking Kitabis pak.
Among them, 63 people (6.84%) have Infection.

Among these 63 people:

How long have people been on Kitabis pak when they have Infection? *

What is the gender of people who have Infection when taking Kitabis pak? *

female: 48.39 %
male: 51.61 %

What is the age of people who have Infection when taking Kitabis pak? *

What are other drugs people take besides Kitabis pak? *

What are other side effects people have besides Infection? *

Cystic Fibrosis (disease of the secretary glands): 11 people, 17.46%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 8 people, 12.70%
Hospitalisation: 6 people, 9.52%
Dyspnea (difficult or laboured breathing): 5 people, 7.94%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 3 people, 4.76%
Cough: 3 people, 4.76%
Rhinovirus Infection: 3 people, 4.76%
Drug Hypersensitivity: 2 people, 3.17%
Limb Injury: 2 people, 3.17%
Nasal Inflammation (inflammation of nose): 2 people, 3.17%

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 47 people, 74.60%
Lung Disorder (lung disease): 10 people, 15.87%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 5 people, 7.94%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 4 people, 6.35%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 4.76%
Bacterial Infection: 2 people, 3.17%
Burkholderia Mallei Infection (infection caused by group of bacteria burkholderia mallei): 2 people, 3.17%
Asthma: 2 people, 3.17%
Respiratory Disorder (respiratory disease): 2 people, 3.17%
Lower Respiratory Tract Infection: 1 person, 1.59%

* Approximation only. Some reports may have incomplete information.

Do you take Kitabis pak and have Infection?

- Check whether Infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kitabis pak:

Kitabis pak (921 reports)

Infection treatments and more:

Infection (201,698 reports)

Browse all side effects of Kitabis pak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infection:

Infection (2,499 drugs)

Browse all the conditions that are associated with Infection:

Infection (2,595 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tobramycin (the active ingredients of Kitabis pak) and Kitabis pak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.